Sheryl Stevenson

Adam Muzychuk, MD, BSc, FRCSC, discusses his ASCRS 2024 presentation on toric lens use for patients with low astigmatism

Greg Kunst, CEO of Aurion Biotech, discusses AURN001, a novel cell therapy targeting corneal endothelial disease

At ASCRS2024, George O. Waring IV, MD, FACS, provides an overview of his presentation highlighting outcomes for LASIK performed using an updated laser ablation algorithm

Sean Hanlon, CEO of CoFi, details the patient and provider benefits of recent CareCredit integration

Rich Small, CEO of Neurotech Pharmaceuticals, provides an update on the months ahead for NT-501 encapsulated cell therapy

Andrew G. Lee, MD, expresses his perspective regarding the necessity of lumbar puncture for all individuals with idiopathic intracranial hypertension, highlighting the importance of clinical judgment and treatment approaches.

Dr Baruch Kuppermann discusses interim results from the first in-human Phase 2 RIPPLE-1 Trial of a dexamethasone implant for diabetic macular oedema and retinal vein occlusion.

Ramin Tadayoni, MD, PhD, highlights data from the BALATON and COMINO Phase 3 studies about faricimab

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.

Mark Blecher, MD, spoke with the Ophthalmology Times team about his poster addressing retinal visualisation and patients who have undergone small aperture IOL implantation at this year's American Academy of Ophthalmology meeting

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Penny Asbell, MD, FACS, presented results from the ARMOR Study

At this year's American Academy of Ophthalmology meeting, the Ophthalmology Times team spoke with Megan Baldwin, MD, founder of Opthea Limited, about the company's ShORe and COAST clinical trials

At AAO 2023, Rich Small, CEO of Neurotech, spoke with our team about the company's development of encapsulated cell therapy, NT-501

At the 2023 AAO meeting, Paul Runge, MD, FACS, spoke with Ophthalmology Times about his time in Ukraine treating retinopathy of prematurity (ROP) and implementing the Norlase Lion laser at this year's American Academy of Ophthalmology meeting.

At this year's American Academy of Ophthalmology meeting, Anthony Wallace, BS, MBA, vice president and general manager of the surgical business at Bausch + Lomb North America, spoke with us about three exciting new launches

Ben Bergo, CEO of Visus Therapeutics, spoke with Ophthalmology Times about the BRIO-I study on presbyopia

Peter K. Kaiser, MD, provides an overview of innovative therapies in development for patients with dry age-related macular degeneration.

Compared with other medical specialties, ophthalmologists typically experience lower burnout rates, explains Peter J. McDonnell, MD.

Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, shares progress in their Phase 2 DR:EAM Diabetic Retinopathy study, with promising results expected in Q1 2024 for their OTT166 eye drop treatment.

Richard B. Rosen, MD, shared insights from his presentation from ASRS 2023 on "New 'MacGyver-inspired' endolaser option for chandelier-assisted scleral buckles" with Sheryl Stevenson, our Group Editorial Director.

Cindy Cai, MD, shared insights from her presentation from ASRS 2023, "Health disparities in lapses in diabetic retinopathy care," with Sheryl Stevenson, our Group Editorial Director.

Dr Ala Moshiri provides an overview of current treatment options for diabetic macular oedema.

Ala Moshiri, MD, PhD, provides an overview of current treatment options for diabetic macular edema.

The various aspects of home monitoring for patients with age-related macular degeneration are discussed in this point/counterpoint by Prof. Rufino Silva, University of Coimbra / Coimbra Hospital and University Centre, Portugal, and Univ.-Prof. Dr. med. Robert P. Finger, PhD, Department of Ophthalmology, University of Bonn, Germany, during the 14th annual Congress on Controversies in Ophthalmology in Lisbon, Portugal.

Pedro Fonseca, MD, Coimbra Hospital and University Centre, Portugal, and Andrew G. Lee, MD, Blanton Eye Institute, Houston Methodist, Texas, United States, discuss the various pros and cons of offering teprotumumab for all patients with thyroid eye disease.

Carl D. Regillo, MD, highlights the Talon Phase 3b results for brolucizumab vs aflibercept in a matched treat-and-extend superiority study for neovascular AMD at the virtual 2023 Angiogenesis conference.

Prof Anat Loewenstein, Chair, Department of Ophthalmology, Tel Aviv Medical Center (Israel), comments on the significance of the US FDA approval of aflibercept for preterm infants with retinopathy.

The company anticipates introducing latanoprost ophthalmic solution 0.005% to U.S. eye care practitioners in the second half of 2023.

At AAO 2022, Dr Mitch Shultz provides discourse on iStent inject vs Hydrus contralateral eye evaluation data.

At AAO 2022, Dr Justis Ehlers presented a talk entitled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"